Price T Rowe Associates Inc Replimune Group, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,962,883 shares of REPL stock, worth $157 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,962,883
Previous 9,879,250
10.97%
Holding current value
$157 Million
Previous $108 Million
22.61%
% of portfolio
0.02%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding REPL
# of Institutions
161Shares Held
74.9MCall Options Held
38.4KPut Options Held
43.7K-
Baker Bros. Advisors LP New York, NY11MShares$158 Million1.48% of portfolio
-
Redmile Group, LLC San Francisco, CA4.91MShares$70.2 Million4.65% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$67.5 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.97MShares$56.8 Million8.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.6MShares$51.5 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $706M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...